No Data
BRII-B: 2024 Annual Report
Hong Kong stocks have fluctuated | The Innovative Drugs Concept has seen significant gains. Institutions state that there is no need to pay tariffs on the licensing fees for Innovative Drugs, and support policies for Innovative Drugs are expected to be gr
The Innovative Drugs Concept has seen significant growth, as of the time of reporting, LAEKNA-B (02105) is up 13.16%, priced at 12.04 Hong Kong dollars; BRII-B (02137) is up 12.35%, priced at 1.82 Hong Kong dollars; CSTONE PHARMA-B (02616) is up 10.88%, priced at 2.65 Hong Kong dollars; BEIGENE (06160) is up 8.27%, priced at 148 Hong Kong dollars; HBM HOLDINGS-B (02142) is up 7.41%, priced at 7.68 Hong Kong dollars.
BRII-B (02137.HK) spent 2.2596 million Hong Kong dollars to repurchase 1.4105 million shares on April 9.
Gelonghui April 9丨BRII-B (02137.HK) announced that on April 9, 2025, it spent 2.2596 million Hong Kong dollars to repurchase 1.4105 million shares, with the repurchase price per share ranging from 1.53 to 1.65 Hong Kong dollars.
On April 7, BRII-B (02137.HK) spent 8.41 million HKD to repurchase 5.31 million shares.
Gelonghui reported on April 7 that BRII-B (02137.HK) announced the repurchase of 5.31 million shares at a cost of 8.41 million Hong Kong dollars on April 7.
Brii Bio Unveils New Data From Its Ongoing Phase 2 ENSURE Study at APASL 2025, Showcasing BRII-179's Unique Potential to Prime and Boost Higher HBsAg Loss Through Target Patient Identification
Preliminary data from Cohort 4 of the ENSURE study supports a novel enrichment strategy to utilize BRII-179 to identify patients who are immune responders and have the potential to achieve higher
Hong Kong stock market movement | BRII-B (02137) dropped over 3% after performance announcement, with annual loss attributable to Shareholders reaching 0.508 billion yuan, an increase of 190.66% year-on-year.
BRII-B (02137) fell over 3% after the report, as of the time of writing, it has dropped by 3.47%, trading at 2.78 HKD, with a turnover of 17.5002 million HKD.
